Vir Biotechnology, Inc. (VIR )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol VIR
- Company Vir Biotechnology, Inc.
- Price $9.73
- Changes Percentage 30.96
- Change 2.30
- Day Low $9.12
- Day High $10.29
- Year High $10.29
- Year Low $4.16
- Market Cap $1,353,686,250
- Price Avg 50 EMA (D) $6.75
- Price Avg 200 EMA (D) $5.69
- Exchange NASDAQ
- Volume 28,794,358
- Average Volume 1,853,726
- Open $9.8
- Previous Close $7.43
- EPS -3.62
- PE -2.69
- Earnings Announcement 2026-04-30 12:00:00
- Shares Outstanding $139,125,000
Company brief: VIR BIOTECHNOLOGY, INC. (VIR )
- Healthcare
- Biotechnology
- Dr. Marianne De Backer M.B.A., M.Sc., Ph.D.
- https://www.vir.bio
- US
- N/A
- 10-11-2019
- US92764N1028
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
VIR Corporation News
What's Happening With VIR Stock?
forbes.com -- Vir Biotechnology (VIR) is experiencing a surge of +58% pre-market due to a significant strategic partnership with Astellas concerning its prostate cancer treatment, VIR-5500, along with encouraging P...
Vir Biotechnology, Inc. (VIR) Q4 2025 Earnings Call Transcript
seekingalpha.com -- Vir Biotechnology, Inc. (VIR) Q4 2025 Earnings Call Transcript...
Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Beats Revenue Estimates
zacks.com -- Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to a loss of $0.76 per share a year ago....